Author: Anthony M. Orbison

Stay informed with free updatesSimply sign up to the Accountancy myFT Digest — delivered directly to your inbox.A plan to reform the rules for qualifying as an accountant in the US could expose firms to discrimination lawsuits and add barriers to joining the profession, according to the body representing the country’s biggest audit firms.In a private comment letter seen by the Financial Times, the Center for Audit Quality — which represents the Big Four and other large firms — condemned proposed reforms as “unnecessarily complex”, and said they could “introduce unconscious bias” into the qualification process.The CAQ’s intervention puts large…

Read More

Cruises come with all sorts of charges, and it can be confusing for passengers. Not everyone pays for their cruise fully at the time they book it, and many manually pay the remaining balance in pieces up until final payment is due. The final payment day is an important one to keep track of because if you owe a balance, your entire cruise can get canceled.If that happens, you may not be eligible for a refund. You could fully lose some of your money or end up with future cruise credit.  Related: Royal Caribbean explains its new strict multi-plug device…

Read More

Dogecoin (DOGE) is trading at dangerously low levels, down 25% in the past two days. Fears are igniting that the token will fall below $0.20. The ongoing crypto market correction phase has sent many of the top cryptocurrencies tumbling down this week. DOGE, as one of the leading meme coins, is getting significant attention for its fall, as investors are worried about further decline.Crypto Expert tweeted on X post highlighting Dogecoin’s recent price trends, noting a potential key support level at $0.22076. The analysis suggests the Dogecoin price is undergoing a corrective phase after a significant 25% dip, raising concerns…

Read More

This is The Takeaway from today’s Morning Brief, which you can sign up to receive in your inbox every morning along with: With its 0.04% gain Thursday, the Dow finally broke its 10-day losing streak, the worst since the 70s. This week’s performance was yet another reminder of why the historically important index is now more historical than important, having long ceded its role to the S&P 500. Before the market’s dramatic reaction to the Fed on Wednesday, the Dow had been running counter to the S&P 500 and Nasdaq and was in a historic funk. A good portion of…

Read More

BEIJING (Reuters) -China’s Nio (NYSE:) on Sunday said it would launch its new Firefly electric vehicle brand in Europe early in the first half of 2025, betting that it would help the company overcome European Union tariffs. William Li, Nio’s CEO, told reporters in Guangzhou that the company will work with local partners on the sale and service of the Firefly in European markets. Nio unveiled the Firefly brand on Saturday and touted it as a rival product to Mercedes’ Smart and BMW (ETR:)’s Mini. The company originally conceived Firefly to boost its market share in Europe but the European…

Read More

New data from market intelligence firm Santiment reveals one altcoin that has seen massive gains this year is rife with whale activity. In a new thread on the social media platform X, Santiment says that among altcoins with at least a $500 million market cap, tokenized artificial intelligence (AI) project Virtuals (VIRTUAL) – an asset that’s up a staggering 20,000% year-to-date – is one of the leaders in terms of whale activity. Santiment also says high-net-worth investors are making moves to accumulate 10 digital assets including VIRTUAL during the latest crypto market crash. “Despite sizable crypto corrections this week, several…

Read More

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called “Santa Claus rallies” can occur near the end of the year. Three Motley Fool contributors think they’ve identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here’s why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (AbbVie): Heading into the tail end of the year, one growth stock which may be due for a rally is AbbVie. The…

Read More

Royal Caribbean Group had an incredible 2024. The cruise line has officially recovered from the Covid pandemic and reinstated its dividend. That once seemed impossible given the level of debt the company took on to survive its nearly 18-month shutdown.But passengers have come back, and the cruise line has exceeded its 2019 profits and passenger levels. CEO Jason Liberty shared his thoughts on the upcoming year during his company’s third-quarter earnings call.  Related: New scam targets Royal Caribbean passengers”While still very early in the planning process, we anticipate earnings in 2025 to start with a $14 (per share) handle. We…

Read More

Ethereum price has stalled at the resistance level of $4,000, but on-chain metrics and other external factors points to more gains. Ethereum (ETH), the second-largest cryptocurrency by market capitalization, was trading at $4,008. But the momentum failed to continue as it has faced resistance over the past three consecutive weeks. Still, ETH has positive catalysts that could push its price higher in the near term. The first main catalyst is that Bitcoin (BTC) has continued rising and moved to a record high this week. Altcoins like Ether often follow the price of Bitcoin. Spot Ethereum ETFs are also seeing strong…

Read More

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time. Nevertheless, there’s an undeniable allure in searching for potential multibagger stocks. Something is captivating about companies with disruptive innovations, whose stocks could be on the cusp of rapid growth and capable of delivering life-changing returns to shareholders. Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising…

Read More